Ixekizumab approved as psoriatic arthritis treatment in the US

A drug called ixekizumab is now available for adults with active psoriatic arthritis in the US. Currently used as a treatment for psoriasis in the UK, Europe and the US, ixekizumab has been found to improve joint symptoms in people with active psoriatic arthritis.

Dr Peter Salzmann, vice president of immunology at Eli Lilly, the company than manufactures ixekizumab, comments:

“Two phase 3 studies demonstrated not only that [ixekizumab] is safe and effective for patients with active psoriatic arthritis who had never been treated with a biologic disease-modifying anti-rheumatic drug, but also for patients with active psoriatic arthritis who have failed or were intolerant to an anti-tumor necrosis factor inhibitor. We are excited to offer a new treatment option that provides significant improvement in joint symptoms and can help both patients and their healthcare providers meet treatment goals.”

Source: Helio Rheumatology

For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.